Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
KYNB
$5.49
+3.98%
KYNB
· Kyntra Bio, Inc.
Market Cap
$21.38M
Shares
4.05M
Volume · Oct 20
13.55K
Avg daily vol (3M)
19.56K
All webcasts
Earnings call · FY2024 Q1
Kyntra Bio, Inc. (KYNB) Q1 2024 Earnings Call
Revenue
$25.36M
-29.9% YoY
Diluted EPS
-$8.25
Net income
-$32.93M
Forward guidance
2 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed May 6, 2024.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Net product revenue under U.S. GAAP
Initiated
full year 2024
|
$120M – $135M | GAAP | |
|
Full year roxadustat net sales in China by FibroGen and the JDE
full year 2024
|
$300M – $340M | — |
Quarter detail
How the reported period landed and where the business moved.
SEC filing · Item 2.02
8-K earnings release
Filed May 6, 2024 · complete as-filed document
SEC periodic report
10-Q report
Filed May 6, 2024 · complete as-filed document